Chang, Shun-Cheng
Chiang, Chien-Ping
Lai, Chih-Hsin
Du, Po-Wen A.
Hung, Yu-Sin
Chen, Yu-Hsuan
Yang, Hui-Yu
Fang, Hao-Yu
Lee, Shiao-Pieng
Tang, Hung-Jen
Wang, Jehng-Kang
Johnson, Michael D.
Lin, Chen-Yong http://orcid.org/0000-0002-6391-2571
Funding for this research was provided by:
National Cancer Institute (CA 123223, P30-CA051008)
National Cancer Institute (CA 123223)
Ministry of National Defense Medical Affairs Bureau, Taiwan (MAB-108-079)
Chi Mei Medical Center, Taiwan (CMNDMC10705, CMNDMC10813)
Shuang-Ho Hospital, Taipei Medical University (TMU105-AE1-B02, N201711050, N201802043, TMU IIT-107-009)
Department of Health, Taipei City Government (10801-62-068)
Taipei City Hospital, Taiwan (TPCH-108-11)
Article History
Received: 21 February 2020
Accepted: 2 June 2020
First Online: 2 July 2020
Compliance with ethical standards
:
: CYL is an inventor on US patents #6,077,938 (Title: Monoclonal antibody to an 80-kDa protease) and #6,677,377 (Title: Structure based discovery of inhibitors of matriptase for the cancer diagnosis and therapy by detection and inhibition of matriptase activity) and MDJ and CYL are inventors on US patent #7,355,015 (Title: Matriptase, a serine protease and its applications).
: Skin specimens were obtained from patients, with written informed consent by the Shuang-Ho Hospital (SHH), Taipei Medical University (TMU) under Institutional Review Board (IRB) protocol (TMU-JIRB Forms 076/20140202; 076/20160306; 071/20160306), approved by the SHH-TMU.